{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:14:23Z","timestamp":1790367263427,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hydroxyurea and blood transfusion therapies remain the main therapeutic strategies for Sickle cell disease. Preliminary data suggest substantial variation and inconsistencies in practice of these two therapeutic modalities in South Asia. In this systematic review we searched Medline, Cochrane library and Scopus for articles on usage of hydroxyurea and blood transfusion therapies for sickle cell disease in South Asia published in English between October 2005 and October 2020.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We selected 41 papers: 33 from India, 3 from Sri Lanka, 2 each from Pakistan and Bangladesh and one from Nepal. Only 14 prospective trials focused on hydroxyurea therapy from which majority (n\u2009=\u200910; 71.4%) adopted fixed low dose (10\u00a0mg\/kg\/day) regimen. With hydroxyurea therapy, 12 and 9 studies reported significant reductions in vaso-occlusive crises and transfusion requirement respectively. Severe anaemia (haemoglobin level\u2009&lt;\u20096\u20137\u00a0g\/dl) was the commonest indicator (n\u2009=\u20098) for transfusion therapy followed by vaso-occlusive crisis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Published data on the hydroxyurea and transfusion therapies in South Asia are limited and heterogeneous. A clear gap of knowledge exists about the nature of the sickle cell disease in the Indian subcontinent particularly from countries outside India necessitating further evidence-based assessments and interventions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01781-w","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T20:03:05Z","timestamp":1616529785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-8734","authenticated-orcid":false,"given":"Thamal","family":"Darshana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuja","family":"Premawardhena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"1781_CR1","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1781_CR2","doi-asserted-by":"publisher","first-page":"e14699-e","DOI":"10.1371\/journal.pone.0014699","volume":"6","author":"J Makani","year":"2011","unstructured":"Makani J, Cox SE, Soka D, Komba AN, Oruo J, Mwamtemi H, et al. Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PLoS ONE. 2011;6(2):e14699-e.","journal-title":"PLoS ONE"},{"issue":"7","key":"1781_CR3","doi-asserted-by":"publisher","first-page":"e1001484","DOI":"10.1371\/journal.pmed.1001484","volume":"10","author":"FB Piel","year":"2013","unstructured":"Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010\u20132050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10(7):e1001484.","journal-title":"PLoS Med"},{"issue":"6","key":"1781_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/bjh.16746","volume":"190","author":"H Bello-Manga","year":"2020","unstructured":"Bello-Manga H, Galadanci AA, Abdullahi S, Ali S, Jibir B, Gambo S, et al. Low educational level of head of household, as a proxy for poverty, is associated with severe anaemia among children with sickle cell disease living in a low-resource setting: evidence from the SPRING trial. Br J Hematol. 2020;190(6):939\u201344.","journal-title":"Br J Hematol"},{"issue":"3","key":"1781_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bjhh.2015.03.013","volume":"37","author":"TAADM Fernandes","year":"2015","unstructured":"Fernandes TAADM, Medeiros TMD, Alves JJP, Bezerra CM, Fernandes JV, Serafim \u00c9SS, et al. Socioeconomic and demographic characteristics of sickle cell disease patients from a low-income region of northeastern Brazil. Rev Bras Hematol Hemoter. 2015;37(3):172\u20137.","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"1","key":"1781_CR6","doi-asserted-by":"publisher","first-page":"17685","DOI":"10.1038\/s41598-018-36077-w","volume":"8","author":"C Hockham","year":"2018","unstructured":"Hockham C, Bhatt S, Colah R, Mukherjee MB, Penman BS, Gupta S, et al. The spatial epidemiology of sickle-cell anaemia in India. Sci Rep. 2018;8(1):17685.","journal-title":"Sci Rep"},{"issue":"4","key":"1781_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4103\/ijcm.IJCM_284_16","volume":"42","author":"D Saxena","year":"2017","unstructured":"Saxena D, Yasobant S, Golechha M. Situational analysis of sickle cell disease in Gujarat, India. Indian J Commun Med. 2017;42(4):218\u201321.","journal-title":"Indian J Commun Med"},{"issue":"12","key":"1781_CR8","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","volume":"4","author":"AM Brandow","year":"2020","unstructured":"Brandow AM, Carroll CP, Creary S, Edwards-Elliott R, Glassberg J, Hurley RW, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656\u2013701.","journal-title":"Blood Adv"},{"issue":"2","key":"1781_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","volume":"4","author":"ST Chou","year":"2020","unstructured":"Chou ST, Alsawas M, Fasano RM, Field JJ, Hendrickson JE, Howard J, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327\u201355.","journal-title":"Blood Adv"},{"key":"1781_CR10","unstructured":"Nigeria FRO. National guideline for the control and management of sickle cell disease. In: Nigeria FMoH, editor. Abuja: Federal Republic of Nigeria; 2014."},{"issue":"10","key":"1781_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","volume":"312","author":"BP Yawn","year":"2014","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033\u201348.","journal-title":"JAMA"},{"issue":"2","key":"1781_CR12","first-page":"e7105","volume":"12","author":"SM AlDallal","year":"2020","unstructured":"AlDallal SM. Voxelotor: a ray of hope for sickle disease. Cureus. 2020;12(2):e7105.","journal-title":"Cureus"},{"issue":"2","key":"1781_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/bjh.14346","volume":"176","author":"BA Davis","year":"2017","unstructured":"Davis BA, Allard S, Qureshi A, Porter JB, Pancham S, Win N, et al. Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. Br J Hematol. 2017;176(2):179\u201391.","journal-title":"Br J Hematol"},{"issue":"2","key":"1781_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/MPH.0000000000000645","volume":"39","author":"A Inati","year":"2017","unstructured":"Inati A, Mansour AG, Sabbouh T, Amhez G, Hachem A, Abbas HA. Transfusion therapy in children with sickle cell disease. J Pediatr Hematol Oncol. 2017;39(2):126\u201332.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1781_CR15","first-page":"003146","volume":"11","author":"WC Wang","year":"2013","unstructured":"Wang WC, Dwan K. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database Syst Rev. 2013;11:003146.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1781_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/asheducation-2016.1.625","volume":"2016","author":"J Howard","year":"2016","unstructured":"Howard J. Sickle cell disease: when and how to transfuse. Hematol Am Soc Hematol Educ Program. 2016;2016(1):625\u201331.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"20","key":"1781_CR17","first-page":"1317","volume":"332","author":"S Charache","year":"1995","unstructured":"Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. J Med. 1995;332(20):1317\u201322.","journal-title":"J Med"},{"issue":"13","key":"1781_CR18","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","volume":"289","author":"MH Steinberg","year":"2003","unstructured":"Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645\u201351.","journal-title":"JAMA"},{"issue":"13","key":"1781_CR19","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMct0708272","volume":"358","author":"OS Platt","year":"2008","unstructured":"Platt OS. Hydroxyurea for the treatment of sickle cell anemia. New Engl J Med. 2008;358(13):1362\u20139.","journal-title":"New Engl J Med"},{"issue":"2","key":"1781_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12288-015-0542-1","volume":"32","author":"SV Deshpande","year":"2016","unstructured":"Deshpande SV, Bhatwadekar SS, Desai P, Bhavsar T, Patel A, Koranne A, et al. Hydroxyurea in sickle cell disease: our experience in western India. Indian J Hematol Blood Transfusion Off J Indian Soc Hematol Blood Transfusion. 2016;32(2):215\u201320.","journal-title":"Indian J Hematol Blood Transfusion Off J Indian Soc Hematol Blood Transfusion"},{"issue":"1","key":"1781_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13023-020-01458-w","volume":"15","author":"T Darshana","year":"2020","unstructured":"Darshana T, Bandara D, Nawarathne U, de Silva U, Costa Y, Pushpakumara K, et al. Sickle cell disease in Sri Lanka: clinical and molecular basis and the unanswered questions about disease severity. Orphanet J Rare Dis. 2020;15(1):177.","journal-title":"Orphanet J Rare Dis"},{"key":"1781_CR22","first-page":"348","volume":"66","author":"H Afzal","year":"2016","unstructured":"Afzal H, Umair SF. Haemoglobin sickle D disease: a presentation with ischaemic stroke. J Pak Med Assoc. 2016;66:348\u201350.","journal-title":"J Pak Med Assoc"},{"key":"1781_CR23","first-page":"154","volume":"68","author":"T Janjua","year":"2018","unstructured":"Janjua T, Haider S, Raza N. Multiple complications in sickle cell anaemia. J Pak Med Assoc. 2018;68:154\u20136.","journal-title":"J Pak Med Assoc"},{"key":"1781_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4038\/sljm.v26i2.40","volume":"26","author":"L Premathilaka","year":"2018","unstructured":"Premathilaka L, Lakmini M, Darshana T, Nawaratne S, Mettananda S, De Silva S, et al. Stroke in sickle beta thalassemia\u2014a case report highlighting pitfalls in management in a low prevalence country. Sri Lanka J Med. 2018;26:55.","journal-title":"Sri Lanka J Med"},{"issue":"2","key":"1781_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12288-017-0851-7","volume":"34","author":"KH Thalagahage","year":"2018","unstructured":"Thalagahage KH, Jayaweera JAAS, Kumbukgolla W, Perera N, Thalagahage E, Kariyawasam J, et al. HbS\/D-Punjab disease: report of 3 cases from Sri Lanka. Indian J Hematol Blood Transfusion Off J Indian Soc Hematol Blood Transfusion. 2018;34(2):350\u20132.","journal-title":"Indian J Hematol Blood Transfusion Off J Indian Soc Hematol Blood Transfusion"},{"issue":"2","key":"1781_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3329\/jdmc.v21i2.15368","volume":"21","author":"M Mollah","year":"2013","unstructured":"Mollah M, Rahman E, Islam S, Morshed A, Munmun F, Shohel M. A young child with sickle cell beta thalassemia: a case report and review of literatures. J Dhaka Med College. 2013;21(2):245\u20139.","journal-title":"J Dhaka Med College"},{"key":"1781_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3329\/bsmmuj.v10i1.31032","volume":"10","author":"M Aziz","year":"2017","unstructured":"Aziz M, Sarkar S, Rahman F, Biswas S, Baqi S, Begum M. Atypical presentation of sickle cell disease. Bangabandhu Sheikh Mujib Med Univ J. 2017;10:27.","journal-title":"Bangabandhu Sheikh Mujib Med Univ J"},{"key":"1781_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3126\/jiom.v34i1.9121","volume":"34","author":"KS Lamsal","year":"2013","unstructured":"Lamsal KS. Sickle cell Anemia with avascular necrosis of femur being managed as rheumatic fever. J Inst Med Nepal. 2013;34:37\u20139.","journal-title":"J Inst Med Nepal"},{"issue":"1","key":"1781_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bcmd.2008.08.003","volume":"42","author":"K Italia","year":"2009","unstructured":"Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, et al. Hydroxyurea in sickle cell disease\u2013a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis. 2009;42(1):25\u201331.","journal-title":"Blood Cells Mol Dis"},{"issue":"1","key":"1781_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4103\/0253-7613.62409","volume":"42","author":"H Singh","year":"2010","unstructured":"Singh H, Dulhani N, Kumar BN, Singh P, Tiwari P. Effective control of sickle cell disease with hydroxyurea therapy. Indian J Pharmacol. 2010;42(1):32\u20135.","journal-title":"Indian J Pharmacol"},{"issue":"5","key":"1781_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/03630269.2012.709897","volume":"36","author":"DK Patel","year":"2012","unstructured":"Patel DK, Mashon RS, Patel S, Das BS, Purohit P, Bishwal SC. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India. Hemoglobin. 2012;36(5):409\u201320.","journal-title":"Hemoglobin"},{"issue":"4","key":"1781_CR32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/03630269.2012.697948","volume":"36","author":"DL Jain","year":"2012","unstructured":"Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Hemoglobin. 2012;36(4):323\u201332.","journal-title":"Hemoglobin"},{"key":"1781_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3126\/jnps.v32i2.5681","volume":"32","author":"BB Lakhkar","year":"2012","unstructured":"Lakhkar BB, Lakhkar BN, Vaswani P. Transcranial Doppler study among children with sickle cell anaemia vs normal children. J Nepal Paediatr Soc. 2012;32:146\u20139.","journal-title":"J Nepal Paediatr Soc"},{"issue":"11","key":"1781_CR34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s13312-012-0217-z","volume":"49","author":"D Jain","year":"2012","unstructured":"Jain D, Italia K, Sarathi V, Ghoshand K, Colah R. Sickle cell anemia from central India: a retrospective analysis. Indian Pediatr. 2012;49(11):911\u20133.","journal-title":"Indian Pediatr"},{"issue":"10","key":"1781_CR35","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s13312-013-0264-0","volume":"50","author":"DL Jain","year":"2013","unstructured":"Jain DL, Apte M, Colah R, Sarathi V, Desai S, Gokhale A, et al. Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience. Indian Pediatr. 2013;50(10):929\u201333.","journal-title":"Indian Pediatr"},{"issue":"3","key":"1781_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12098-013-1163-z","volume":"81","author":"V Mehta","year":"2014","unstructured":"Mehta V, Mistry A, Raicha B, Italia Y, Serjeant G. Transfusion in sickle cell disease: experience from a Gujarat centre. Indian J Pediatr. 2014;81(3):234\u20137.","journal-title":"Indian J Pediatr"},{"issue":"21","key":"1781_CR37","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1182\/blood.V122.21.1000.1000","volume":"122","author":"DL Jain","year":"2013","unstructured":"Jain DL, Krishnamurti L, Sarathi V, Desai S, Gokhale A. Long term safety and efficacy of low fixed dose hydroxyurea in pediatric patients with sickle cell anemia: a single center study from central India. Blood. 2013;122(21):1000.","journal-title":"Blood"},{"issue":"3","key":"1781_CR38","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1097\/MPH.0000000000000049","volume":"36","author":"S Oberoi","year":"2014","unstructured":"Oberoi S, Das R, Trehan A, Ahluwalia J, Bansal D, Malhotra P, et al. HbSD-Punjab: clinical and hematological profile of a rare hemoglobinopathy. J Pediatr Hematol Oncol. 2014;36(3):e140\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"3","key":"1781_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/MOH.0000000000000029","volume":"21","author":"R Colah","year":"2014","unstructured":"Colah R, Mukherjee M, Ghosh K. Sickle cell disease in India. Curr Opin Hematol. 2014;21(3):215\u201323.","journal-title":"Curr Opin Hematol"},{"issue":"8","key":"1781_CR40","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/pbc.25004","volume":"61","author":"S Patel","year":"2014","unstructured":"Patel S, Purohit P, Mashon RS, Dehury S, Meher S, Sahoo S, et al. The effect of hydroxyurea on compound heterozygotes for sickle cell-hemoglobin D-Punjab\u2014a single centre experience in eastern India. Pediatr Blood Cancer. 2014;61(8):1341\u20136.","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"1781_CR41","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/pbc.24723","volume":"61","author":"V Nimgaonkar","year":"2014","unstructured":"Nimgaonkar V, Krishnamurti L, Prabhakar H, Menon N. Comprehensive integrated care for patients with sickle cell disease in a remote aboriginal tribal population in southern India. Pediatr Blood Cancer. 2014;61(4):702\u20135.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"1781_CR42","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/pbc.25391","volume":"62","author":"S Dehury","year":"2015","unstructured":"Dehury S, Purohit P, Patel S, Meher S, Kullu BK, Sahoo LK, et al. Low and fixed dose of hydroxyurea is effective and safe in patients with HbS\u03b2+ thalassemia with IVS1\u20135(G\u2192C) mutation. Pediatric Blood Cancer. 2015;62(6):1017\u201323.","journal-title":"Pediatric Blood Cancer"},{"issue":"1","key":"1781_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/bjh.13083","volume":"168","author":"K Italia","year":"2015","unstructured":"Italia K, Kangne H, Shanmukaiah C, Nadkarni AH, Ghosh K, Colah RB. Variable phenotypes of sickle cell disease in India with the Arab-Indian haplotype. Br J Haematol. 2015;168(1):156\u20139.","journal-title":"Br J Haematol"},{"issue":"1","key":"1781_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0969141314557372","volume":"22","author":"Y Italia","year":"2015","unstructured":"Italia Y, Krishnamurti L, Mehta V, Raicha B, Italia K, Mehta P, et al. Feasibility of a newborn screening and follow-up programme for sickle cell disease among South Gujarat (India) tribal populations. J Med Screen. 2015;22(1):1\u20137.","journal-title":"J Med Screen"},{"issue":"1","key":"1781_CR45","doi-asserted-by":"publisher","first-page":"e0147081","DOI":"10.1371\/journal.pone.0147081","volume":"11","author":"DS Upadhye","year":"2016","unstructured":"Upadhye DS, Jain DL, Trivedi YL, Nadkarni AH, Ghosh K, Colah RB. Neonatal screening and the clinical outcome in children with sickle cell disease in central India. PLoS ONE. 2016;11(1):e0147081.","journal-title":"PLoS ONE"},{"issue":"4","key":"1781_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4103\/0971-5916.184282","volume":"143","author":"GR Serjeant","year":"2016","unstructured":"Serjeant GR. Evolving locally appropriate models of care for indian sickle cell disease. Indian J Med Res. 2016;143(4):405\u201313.","journal-title":"Indian J Med Res"},{"issue":"10","key":"1781_CR47","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s12098-016-2081-7","volume":"83","author":"D Jain","year":"2016","unstructured":"Jain D, Warthe V, Dayama P, Sarate D, Colah R, Mehta P, et al. Sickle cell disease in central India: a potentially severe syndrome. Indian J Pediatr. 2016;83(10):1071\u20136.","journal-title":"Indian J Pediatr"},{"issue":"10","key":"1781_CR48","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1002\/pbc.26085","volume":"63","author":"D Jain","year":"2016","unstructured":"Jain D, Arjunan A, Sarathi V, Jain H, Bhandarwar A, Vuga M, et al. Clinical events in a large prospective cohort of children with sickle cell disease in Nagpur, India: evidence against a milder clinical phenotype in India. Pediatr Blood Cancer. 2016;63(10):1814\u201321.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"1781_CR49","first-page":"558","volume":"21","author":"R Yadav","year":"2016","unstructured":"Yadav R, Lazarus M, Ghanghoria P, Singh M, Gupta RB, Kumar S, et al. Sickle cell disease in Madhya Pradesh, Central India: a comparison of clinical profile of sickle cell homozygote vs sickle-beta thalassaemia individuals. Hematology (Amsterdam, Netherlands). 2016;21(9):558\u201363.","journal-title":"Hematology (Amsterdam, Netherlands)."},{"issue":"1","key":"1781_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41043-017-0079-z","volume":"36","author":"G Desai","year":"2017","unstructured":"Desai G, Anand A, Shah P, Shah S, Dave K, Bhatt H, et al. Sickle cell disease and pregnancy outcomes: a study of the community-based hospital in a tribal block of Gujarat, India. J Health Popul Nutr. 2017;36(1):3.","journal-title":"J Health Popul Nutr"},{"issue":"3","key":"1781_CR51","first-page":"19","volume":"11","author":"P Mohanty","year":"2017","unstructured":"Mohanty P, Jena RK, Sethy S. Variability of iron load in patients of sickle cell anaemia (HbSS): a study from Eastern India. J Clin Diagn Res. 2017;11(3):19\u201322.","journal-title":"J Clin Diagn Res"},{"issue":"6","key":"1781_CR52","first-page":"22","volume":"65","author":"LK Sahoo","year":"2017","unstructured":"Sahoo LK, Kullu BK, Patel S, Patel NK, Rout P, Purohit P, et al. Study of seminal fluid parameters and fertility of male sickle cell disease patients and potential impact of hydroxyurea treatment. J Assoc Physicians India. 2017;65(6):22\u20135.","journal-title":"J Assoc Physicians India"},{"issue":"2","key":"1781_CR53","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s12288-017-0869-x","volume":"34","author":"S Sethy","year":"2018","unstructured":"Sethy S, Panda T, Jena RK. Beneficial effect of low fixed dose of hydroxyurea in vaso-occlusive crisis and transfusion requirements in adult hbss patients: a prospective study in a tertiary care center. Indian J Hematol Blood Transfusion Off J Indian Soc Hematol Blood Transfusion. 2018;34(2):294\u20138.","journal-title":"Indian J Hematol Blood Transfusion Off J Indian Soc Hematol Blood Transfusion"},{"issue":"3","key":"1781_CR54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/MOH.0000000000000422","volume":"25","author":"D Jain","year":"2018","unstructured":"Jain D, Mohanty D. Clinical manifestations of sickle cell disease in India: misconceptions and reality. Curr Opin Hematol. 2018;25(3):171\u20136.","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"1781_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/ijmr.IJMR_940_17","volume":"149","author":"K Jariwala","year":"2019","unstructured":"Jariwala K, Mishra K, Ghosh K. Comparative study of alloimmunization against red cell antigens in sickle cell disease & thalassaemia major patients on regular red cell transfusion. Indian J Med Res. 2019;149(1):34\u201340.","journal-title":"Indian J Med Res"},{"issue":"4","key":"1781_CR56","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/tropicalmed4040125","volume":"4","author":"K Dave","year":"2019","unstructured":"Dave K, Chinnakali P, Thekkur P, Desai S, Vora C, Desai G. Attrition from care and clinical outcomes in a cohort of sickle cell disease patients in a tribal area of Western India. Trop Med Infect Dis. 2019;4(4):125.","journal-title":"Trop Med Infect Dis"},{"key":"1781_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.32677\/IJCH.2020.v07.i01.008","volume":"07","author":"A Somkuwar","year":"2020","unstructured":"Somkuwar A, Bokade C, Merchant S, Meshram R, Mahalinge M, Somkuwar T. Short-term safety and beneficial effects of hydroxyurea therapy in children with sickle cell disease. Indian J Child Health. 2020;07:29\u201332.","journal-title":"Indian J Child Health"},{"issue":"1","key":"1781_CR58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12687-019-00410-1","volume":"11","author":"S Sinha","year":"2020","unstructured":"Sinha S, Seth T, Colah RB, Bittles AH. Haemoglobinopathies in India: estimates of blood requirements and treatment costs for the decade 2017\u20132026. J Commun Genet. 2020;11(1):39\u201345.","journal-title":"J Commun Genet"},{"issue":"4","key":"1781_CR59","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/ijmr.IJMR_1946_18","volume":"151","author":"D Jain","year":"2020","unstructured":"Jain D, Tokalwar R, Upadhye D, Colah R, Serjeant GR. Homozygous sickle cell disease in Central India & Jamaica: a comparison of newborn cohorts. Indian J Med Res. 2020;151(4):326\u201332.","journal-title":"Indian J Med Res"},{"issue":"7","key":"1781_CR60","first-page":"493","volume":"7","author":"SK Barma","year":"2020","unstructured":"Barma SK, Dash MR, Samal SR, Sethy G, Panigrahi P. Effect of hydroxyurea on clinical and haematological profile of children with sickle cell anaemia. Int J Res Rev. 2020;7(7):493\u20139.","journal-title":"Int J Res Rev"},{"issue":"26","key":"1781_CR61","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1182\/blood-2014-08-435768","volume":"124","author":"TE Wong","year":"2014","unstructured":"Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. Blood. 2014;124(26):3850\u20137.","journal-title":"Blood"},{"issue":"12","key":"1781_CR62","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1016\/S2352-3026(19)30200-5","volume":"6","author":"N Roberts","year":"2019","unstructured":"Roberts N, James S, Delaney M, Fitzmaurice C. The global need and availability of blood products: a modelling study. Lancet Haematol. 2019;6(12):e606\u201315.","journal-title":"Lancet Haematol"},{"issue":"3","key":"1781_CR63","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/bjh.14437","volume":"176","author":"A Premawardhena","year":"2017","unstructured":"Premawardhena A, Allen A, Piel F, Fisher C, Perera L, Rodrigo R, et al. The evolutionary and clinical implications of the uneven distribution of the frequency of the inherited haemoglobin variants over short geographical distances. Br J Hematol. 2017;176(3):475\u201384.","journal-title":"Br J Hematol"},{"key":"1781_CR64","doi-asserted-by":"publisher","first-page":"659191","DOI":"10.5402\/2012\/659191","volume":"2012","author":"MM Uddin","year":"2012","unstructured":"Uddin MM, Akteruzzaman S, Rahman T, Hasan AK, Shekhar HU. Pattern of \u03b2-thalassemia and other haemoglobinopathies: a cross-sectional study in Bangladesh. ISRN Hematol. 2012;2012:659191.","journal-title":"ISRN Hematol"},{"key":"1781_CR65","first-page":"1","volume":"7","author":"W Khan","year":"2017","unstructured":"Khan W, Banu B, Sadiya S, Sarwardi G. Spectrum of types of thalassemias and hemoglobinopathies: study in a tertiary level children hospital in Bangladesh. Thalassemia Rep. 2017;7:1.","journal-title":"Thalassemia Rep"},{"issue":"1","key":"1781_CR66","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s13104-019-4762-6","volume":"12","author":"N Gautam","year":"2019","unstructured":"Gautam N, Gaire B, Manandhar T, Marasini BP, Parajuli N, Lekhak SP, et al. Glucose 6 phosphate dehydrogenase deficiency and hemoglobinopathy in South Western Region Nepal: a boon or burden. BMC Res Notes. 2019;12(1):734.","journal-title":"BMC Res Notes"},{"issue":"1","key":"1781_CR67","doi-asserted-by":"publisher","first-page":"52","DOI":"10.33314\/jnhrc.v18i1.2303","volume":"18","author":"RM Shrestha","year":"2020","unstructured":"Shrestha RM, Pandit R, Yadav UK, Das R, Yadav BK, Upreti HC. Distribution of hemoglobinopathy in Nepalese population. J Nepal Health Res Council. 2020;18(1):52\u20138.","journal-title":"J Nepal Health Res Council"},{"issue":"4\u20136","key":"1781_CR68","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/03630269.2017.1414058","volume":"41","author":"M Marchand","year":"2017","unstructured":"Marchand M, Gill C, Malhotra AK, Bell C, Busto E, McKeown MD, et al. The assessment and sustainable management of sickle cell disease in the indigenous Tharu population of Nepal. Hemoglobin. 2017;41(4\u20136):278\u201382.","journal-title":"Hemoglobin"},{"key":"1781_CR69","first-page":"174","volume":"11","author":"J Hussain","year":"2013","unstructured":"Hussain J, Arif S, Zamir S, Mahsud M, Jahan S. Pattern of thalassemias and other hemoglobinopathies: a study in district Dera Ismail Khan. Pak Gomal Med J Sci. 2013;11:174\u20137.","journal-title":"Pak Gomal Med J Sci"},{"issue":"3","key":"1781_CR70","first-page":"119","volume":"16","author":"D Sameen","year":"2018","unstructured":"Sameen D, Parveen S, Danish F, Salam H, Agha A, Sharafat S. Sickle cell anemia in sheedi population of lyari: hemoglobinopathy seen in a neglected population. Intjpathol. 2018;16(3):119\u201322.","journal-title":"Intjpathol"},{"issue":"8","key":"1781_CR71","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00277-008-0495-7","volume":"87","author":"NK Hashmi","year":"2008","unstructured":"Hashmi NK, Moiz B, Nusrat M, Hashmi MR. Chromatographic analysis of Hb S for the diagnosis of various sickle cell disorders in Pakistan. Ann Hematol. 2008;87(8):639\u201345.","journal-title":"Ann Hematol"},{"issue":"10019","key":"1781_CR72","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","volume":"387","author":"RE Ware","year":"2016","unstructured":"Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet (London, England). 2016;387(10019):661\u201370.","journal-title":"Lancet (London, England)"},{"issue":"6","key":"1781_CR73","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.3324\/haematol.2019.231407","volume":"105","author":"RO Opoka","year":"2020","unstructured":"Opoka RO, Hume HA, Latham TS, Lane A, Williams O, Tymon J, et al. Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica. 2020;105(6):e272\u20135.","journal-title":"Haematologica"},{"issue":"17","key":"1781_CR74","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","volume":"119","author":"RE Ware","year":"2012","unstructured":"Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119(17):3925\u201332.","journal-title":"Blood"},{"issue":"11","key":"1781_CR75","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/ajh.23547","volume":"88","author":"O Alvarez","year":"2013","unstructured":"Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013;88(11):932\u20138.","journal-title":"Am J Hematol"},{"key":"1781_CR76","unstructured":"Government of India MoHFW. Prevention and control of hemoglobinopathies in India -thalassemias, sickle cell disease and other variant hemoglobins. In: Mission NH, editor. New Delhi: Government of India, Ministry of Health & Family Welfare; 2016. p. 83\u20136."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01781-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01781-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01781-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T07:10:04Z","timestamp":1675062604000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01781-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1781"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01781-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"7 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}